Radiopharm Theranostics Ltd (RDPTF) — SEC Filings
Radiopharm Theranostics Ltd (RDPTF) — 50 SEC filings. Latest: 6-K (Dec 19, 2025). Includes 48 6-K, 1 20-F/A, 1 20-F.
View Radiopharm Theranostics Ltd on SEC EDGAR
Overview
Radiopharm Theranostics Ltd (RDPTF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 19, 2025: Radiopharm Theranostics Ltd, a pharmaceutical preparations company, filed a Form 6-K on December 19, 2025. The filing is a report of a foreign private issuer and indicates the company will file annual reports under Form 20-F. The company's principal executive office is located at Level 3, 62 Lygon S
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bearish, 49 neutral. The dominant filing sentiment for Radiopharm Theranostics Ltd is neutral.
Filing Type Overview
Radiopharm Theranostics Ltd (RDPTF) has filed 48 6-K, 1 20-F/A, 1 20-F with the SEC between Dec 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of RDPTF's 46 recent filings, 1 were flagged as high-risk, 1 as medium-risk, and 44 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Riccardo Canevari
- Paul Hopper
- Ian Turner
- Hester Larkin
- Leila Alland
- Phillip Hains
- Noel Donnelly
Industry Context
Radiopharm Theranostics operates in the highly competitive and innovation-driven biopharmaceutical sector, focusing on radiopharmaceuticals for cancer diagnosis and therapy. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include the advancement of targeted therapies, personalized medicine, and the integration of diagnostic imaging with therapeutic agents (theranostics).
Top Tags
foreign-private-issuer (43) · sec-filing (21) · reporting (15) · regulatory-filing (12) · 6-K (10) · 6-k (5) · disclosure (3) · Biotechnology (2) · administrative (2) · regulatory (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Granted Patents | 34 | Number of patents owned or licensed by Radiopharm Theranostics Ltd, indicating its intellectual property strength. |
| Board Meetings | 7 | Number of Board of Directors meetings held during the fiscal year ended June 30, 2025, showing active governance. |
| Audit Committee Meetings | 3 | Number of Audit Committee meetings held during the fiscal year ended June 30, 2025, indicating oversight activity. |
| Remuneration Committee Meetings | 3 | Number of Remuneration Committee meetings held during the fiscal year ended June 30, 2025, showing executive compensation oversight. |
| PD-L1-a China Patent Expiry | 2036 | Earliest expiry date for a key PD-L1 patent in a major market. |
| PD-L1-b US Patent Expiry | 2039 | Latest expiry date for a key PD-L1 patent in a major market. |
| HER-2 Patent Expiry | 2038 | Expiry date for the HER-2 patent in China, Japan, and US. |
| PTK7 Earliest Patent Expiry | 2041 | Earliest expiry date for the PTK7 patent, indicating long-term protection for a newer asset. |
| PSA-mAb US/Europe Patent Expiry | 2037 | Expiry date for the PSA-mAb patent in key markets like US and Europe. |
| Ordinary Shares Outstanding | 2,364,949,502 | Total ordinary shares outstanding as of June 30, 2025, relevant for per-share metrics. |
| Commission File Number | 001-41621 | Identifies the company's SEC filing history |
| SEC File Number | 001-41621 | Identifies the company's filing history with the SEC. |
| Total Comprehensive Loss | A$37.88M | For the fiscal year ended June 30, 2025, indicating significant operating losses. |
| Negative Cash Flows from Operating Activities | A$36.65M | For the fiscal year ended June 30, 2025, highlighting cash burn. |
| Accumulated Losses | A$145.73M | As of June 30, 2025, demonstrating a history of unprofitability. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Radiopharm Theranostics Ltd (RDPTF)?
Radiopharm Theranostics Ltd has 50 recent SEC filings from Dec 2024 to Dec 2025, including 48 6-K, 1 20-F/A, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RDPTF filings?
Across 50 filings, the sentiment breakdown is: 1 bearish, 49 neutral. The dominant sentiment is neutral.
Where can I find Radiopharm Theranostics Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Radiopharm Theranostics Ltd (RDPTF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Radiopharm Theranostics Ltd?
Financial highlights for Radiopharm Theranostics Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for RDPTF?
The investment thesis for RDPTF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Radiopharm Theranostics Ltd?
Key executives identified across Radiopharm Theranostics Ltd's filings include Riccardo Canevari, Paul Hopper, Ian Turner, Hester Larkin, Leila Alland and 2 others.
What are the main risk factors for Radiopharm Theranostics Ltd stock?
Of RDPTF's 46 assessed filings, 1 were flagged high-risk, 1 medium-risk, and 44 low-risk.
What are recent predictions and forward guidance from Radiopharm Theranostics Ltd?
Forward guidance and predictions for Radiopharm Theranostics Ltd are extracted from SEC filings as they are enriched.